

Armin Ghobadi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1844199/publications.pdf>

Version: 2024-02-01

88
papers

11,091
citations

218677

26
h-index

62596

80
g-index

88
all docs

88
docs citations

88
times ranked

9733
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	27.0	3,865
2	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741
3	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	10.7	1,467
4	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	27.0	663
5	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	27.0	586
6	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	8.2	498
7	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	1.6	481
8	An “off-the-shelf“-fratricide-resistant CART-T for the treatment of T cell hematologic malignancies. <i>Leukemia</i> , 2018, 32, 1970-1983.	7.2	282
9	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	5.2	238
10	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
11	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
12	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). <i>Blood</i> , 2019, 134, 764-764.	1.4	77
13	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. <i>Cancer</i> , 2019, 125, 4181-4192.	4.1	61
14	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	1.2	61
15	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabm1375.	12.4	49
16	Long-Term (–4 Year and –5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 1764-1764.	1.4	48
17	Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. <i>Current Research in Translational Medicine</i> , 2018, 66, 43-49.	1.8	45
18	CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. <i>American Journal of Transplantation</i> , 2021, 21, 809-814.	4.7	44

#	ARTICLE	IF	CITATIONS
19	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	5.2	40
20	Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1072-1077.	2.0	39
21	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	5.2	39
22	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Blood</i> , 2019, 134, 245-245.	1.4	37
23	Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1324-1329.	2.0	35
24	Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 823-823.	1.4	33
25	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2016, 49, 1-6.	0.8	31
26	Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis. <i>Blood</i> , 2014, 124, 2752-2754.	1.4	27
27	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.	1.4	26
28	The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 589-592.	4.7	22
29	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2220-2231.	7.2	20
30	[¹⁸ F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. <i>Molecular Therapy</i> , 2015, 23, 1110-1122.	8.2	18
31	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 285-289.	0.4	17
32	Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3003-3003.	1.6	17
33	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e404-e407.	3.5	16
34	Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2-2.	1.4	16
35	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2021, 138, 744-744.	1.4	15
36	CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. <i>Leukemia</i> , 2022, 36, 1625-1634.	7.2	15

#	ARTICLE	IF	CITATIONS
37	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3776-3783.	7.0	14
38	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. <i>Current Research in Translational Medicine</i> , 2019, 67, 51-55.	1.8	13
39	Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, e373-e375.	3.5	13
40	Hematopoietic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. <i>Frontiers in Oncology</i> , 2020, 10, 608916.	2.8	13
41	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucl (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2018, 132, 2967-2967.	1.4	13
42	Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. <i>Cancers</i> , 2021, 13, 5181.	3.7	13
43	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1041-1048.	1.8	12
44	Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucl (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3039-3039.	1.6	12
45	KarMMA-3: A Phase 3 Study of Idecabtagene Vicleucl (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 24-25.	1.4	11
46	Real-World Outcomes of Axicabtagene Ciloleucl (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. <i>Blood</i> , 2021, 138, 530-530.	1.4	9
47	Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2155-2158.	2.0	8
48	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucl (Axi-Cel). <i>Blood</i> , 2020, 136, 40-42.	1.4	8
49	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 818679.	2.8	8
50	Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. <i>Leukemia Research</i> , 2018, 72, 86-91.	0.8	7
51	Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R) Tj ETQq1 1 0.784314 rgBT/Ov	0.784314	7
52	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e588-e593.	0.4	6
53	A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL). <i>Blood</i> , 2021, 138, 4829-4829.	1.4	6
54	Real-world outcomes of axicabtagene ciloleucl (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7571-7571.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice. <i>Blood</i> , 2018, 131, 2594-2596.	1.4	5
56	Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7552-7552.	1.6	5
57	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
58	Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e363-e364.	0.4	4
59	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2021, 5, 191-203.	3.0	4
60	Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/ α^{\sim} TIM-3 α^{\sim} CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3022-3022.	1.6	4
61	Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. <i>Blood</i> , 2021, 138, 3826-3826.	1.4	4
62	Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2020, 136, 3-4.	1.4	4
63	Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7010-7010.	1.6	4
64	Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.4	3
65	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. <i>Blood</i> , 2020, 136, 46-48.	1.4	3
66	Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7548-7548.	1.6	3
67	Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19583-e19583.	1.6	3
68	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1441-1449.	1.3	2
69	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. <i>Bone Marrow Transplantation</i> , 2021, 56, 2016-2018.	2.4	2
70	CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. <i>Lancet, The</i> , 2021, 398, 1109-1110.	18.7	2
71	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
72	Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study. <i>Blood</i> , 2021, 138, 2841-2841.	1.4	2

#	ARTICLE	IF	CITATIONS
73	End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 3506-3506.	1.4	2
74	Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD). <i>Blood</i> , 2021, 138, 3853-3853.	1.4	2
75	Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1188-1190.	2.4	1
76	Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. <i>Blood</i> , 2018, 132, 5666-5666.	1.4	1
77	CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3098-3098.	1.4	1
78	Disparities in Healthcare Resource Utilization for Multiple Myeloma. <i>Blood</i> , 2018, 132, 4793-4793.	1.4	1
79	Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 5627-5627.	1.4	1
80	A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 8-9.	1.4	1
81	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 903-914.	2.4	1
82	Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3196-3196.	1.4	0
83	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. <i>Blood</i> , 2018, 132, 5277-5277.	1.4	0
84	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4463-4463.	1.4	0
85	The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3439-3439.	1.4	0
86	Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5701-5701.	1.4	0
87	Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein-Barr Virus Viremia. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
88	Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-17 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7596-TPS7596.	1.6	0